A 12-week, randomised, double-blind, placebo-controlled, parallel three-group study to assess the safety, tolerability and efficacy of two dose levels of PBT2 to slow progression of disease in patients with early Alzheimer's disease

Trial Profile

A 12-week, randomised, double-blind, placebo-controlled, parallel three-group study to assess the safety, tolerability and efficacy of two dose levels of PBT2 to slow progression of disease in patients with early Alzheimer's disease

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2014

At a glance

  • Drugs PBT 2 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EURO
  • Sponsors Prana Biotechnology
  • Most Recent Events

    • 17 Jul 2014 According to the Prana Biotechnology media release, data from this trial was presented at the Alzheimer's Association International Conference 12-14 Jul 2014.
    • 10 Jul 2009 Results, as part of a featured research symposium, will be presented at the 2009 International Conference on Alzheimer's Disease (ICAD) according to a Prana Biotechnology media release.
    • 07 Aug 2008 Results published in the Lancet Neurology Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top